MiR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2018 Nov 30

PMID 30497054

Citations 14

Authors

Arulraj Nadaradjane

Josephine Briand

Gwenola Bougras-Cartron

Valentine Disdero

Francois M Vallette

Jean-Sebastien Frenel

Pierre-Francois Cartron

Affiliations

Soon will be listed here.

Abstract

In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the "Prognostic miRNA Database" indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p). Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker.

Citing Articles

The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer.

Fang Q Cancers (Basel). 2024; 16(2).

PMID: 38254819 PMC: 10814553. DOI: 10.3390/cancers16020331.

Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.

Tabnak P, Hasanzade Bashkandi A, Ebrahimnezhad M, Soleimani M Cancer Cell Int. 2023; 23(1):238.

PMID: 37821870 PMC: 10568859. DOI: 10.1186/s12935-023-03090-7.

A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.

Hasan H, Afzal M, Castresana J, Shahi M Cells. 2023; 12(12).

PMID: 37371047 PMC: 10297163. DOI: 10.3390/cells12121578.

Systematic characterization and biological functions of non-coding RNAs in glioblastoma.

Dai L, Liang W, Shi Z, Li X, Zhou S, Hu W Cell Prolif. 2022; 56(3):e13375.

PMID: 36457281 PMC: 9977673. DOI: 10.1111/cpr.13375.

Decrease of circARID1A retards glioblastoma invasion by modulating miR-370-3p/ TGFBR2 pathway.

Li B, Chen J, Wu Y, Luo H, Ke Y Int J Biol Sci. 2022; 18(13):5123-5135.

PMID: 35982888 PMC: 9379412. DOI: 10.7150/ijbs.66673.

References

Nandi D, Cheema P, Jaiswal N, Nag A . FoxM1: Repurposing an oncogene as a biomarker. Semin Cancer Biol. 2017; 52(Pt 1):74-84. DOI: 10.1016/j.semcancer.2017.08.009. View

Martin C . Oncolytic Viruses: Treatment and Implications for Patients With Gliomas . Clin J Oncol Nurs. 2017; 21(2 Suppl):60-64. DOI: 10.1188/17.CJON.S2.60-64. View

Cheray M, Pacaud R, Nadaradjane A, Oliver L, Vallette F, Cartron P . Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth. Theranostics. 2016; 6(11):1988-1999. PMC: 5039338. DOI: 10.7150/thno.9150. View

Yungang W, Xiaoyu L, Pang T, Wenming L, Pan X . miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother. 2013; 68(2):149-54. DOI: 10.1016/j.biopha.2013.08.008. View

Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q . Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 2014; 33:9. PMC: 3917617. DOI: 10.1186/1756-9966-33-9. View

Gao W, He H, Wang Z, Zhao H, Lian X, Wang Y . Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 2012; 11:55. PMC: 3439335. DOI: 10.1186/1476-511X-11-55. View

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes T . Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 2014; 9(3):704-14. PMC: 5528696. DOI: 10.1016/j.molonc.2014.11.004. View

Liu X, Huang Y, Jin C, Zhou Y, Chen X, Li J . MicroRNA-370 inhibits the growth and metastasis of lung cancer by down-regulating epidermal growth factor receptor expression. Oncotarget. 2017; 8(50):88139-88151. PMC: 5675699. DOI: 10.18632/oncotarget.21537. View

Lin X, Wang Z, Wang Y, Feng W . Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia. Int J Clin Exp Pathol. 2016; 8(11):14658-66. PMC: 4713575. View

10.

Chen L, Kang C . miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks. Oncotarget. 2015; 6(36):38628-42. PMC: 4770725. DOI: 10.18632/oncotarget.5926. View

11.

Ahir B, Ozer H, Engelhard H, Lakka S . MicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review. Crit Rev Oncol Hematol. 2017; 120:22-33. DOI: 10.1016/j.critrevonc.2017.10.003. View

12.

Schaller T, Sampson J . Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Rev Vaccines. 2016; 16(1):27-36. PMC: 5479410. DOI: 10.1080/14760584.2016.1218762. View

13.

Lo S, Hung P, Chen J, Tu H, Fang W, Chen C . Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma. Oncogene. 2011; 31(2):226-37. DOI: 10.1038/onc.2011.226. View

14.

Wei S, Ma W . MiR-370 functions as oncogene in melanoma by direct targeting pyruvate dehydrogenase B. Biomed Pharmacother. 2017; 90:278-286. DOI: 10.1016/j.biopha.2017.03.068. View

15.

Mercatelli N, Galardi S, Ciafre S . MicroRNAs as Multifaceted Players in Glioblastoma Multiforme. Int Rev Cell Mol Biol. 2017; 333:269-323. DOI: 10.1016/bs.ircmb.2017.03.002. View

16.

Cheray M, Nadaradjane A, Bonnet P, Routier S, Vallette F, Cartron P . Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness. Epigenomics. 2014; 6(3):267-75. DOI: 10.2217/epi.14.18. View

17.

Cheray M, Pacaud R, Nadaradjane A, Vallette F, Cartron P . Specific inhibition of one DNMT1-including complex influences tumor initiation and progression. Clin Epigenetics. 2013; 5(1):9. PMC: 3727981. DOI: 10.1186/1868-7083-5-9. View

18.

Liu H, Yang N, Fei Z, Qiu J, Ma D, Liu X . Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. Biomed Rep. 2016; 5(3):332-336. PMC: 4998167. DOI: 10.3892/br.2016.726. View

19.

Tan A, Heimberger A, Khasraw M . Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep. 2017; 19(4):23. DOI: 10.1007/s11912-017-0586-5. View

20.

Gao Y, Chen X, Liu H . Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Sci Rep. 2016; 6:32972. PMC: 5011744. DOI: 10.1038/srep32972. View